Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1994 1
1996 2
1997 1
1998 1
1999 3
2000 2
2001 1
2002 5
2003 1
2004 1
2005 2
2006 2
2007 3
2008 3
2009 2
2010 10
2011 5
2012 6
2013 3
2014 3
2015 4
2016 3
2017 3
2018 2
2019 8
2020 5
2021 8
2022 7
2023 6
2024 10
2025 12
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
The Value of Delaying Alzheimer's Disease Onset.
Zissimopoulos J, Crimmins E, St Clair P. Zissimopoulos J, et al. Forum Health Econ Policy. 2014 Nov;18(1):25-39. doi: 10.1515/fhep-2014-0013. Epub 2014 Nov 4. Forum Health Econ Policy. 2014. PMID: 27134606 Free PMC article.
Alzheimer's disease (AD) extracts a heavy societal toll. The value of medical advances that delay onset of AD could be significant. ...We find Medical advances delaying onset of AD generate significant economic and longevity …
Alzheimer's disease (AD) extracts a heavy societal toll. The value of medical advances that delay onse …
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.
Bateman RJ, Li Y, McDade EM, Llibre-Guerra JJ, Clifford DB, Atri A, Mills SL, Santacruz AM, Wang G, Supnet C, Benzinger TLS, Gordon BA, Ibanez L, Klein G, Baudler M, Doody RS, Delmar P, Kerchner GA, Bittner T, Wojtowicz J, Bonni A, Fontoura P, Hofmann C, Kulic L, Hassenstab J, Aschenbrenner AJ, Perrin RJ, Cruchaga C, Renton AE, Xiong C, Goate AA, Morris JC, Holtzman DM, Snider BJ, Mummery C, Brooks WS, Wallon D, Berman SB, Roberson E, Masters CL, Galasko DR, Jayadev S, Sanchez-Valle R, Pariente J, Kinsella J, van Dyck CH, Gauthier S, Hsiung GR, Masellis M, Dubois B, Honig LS, Jack CR, Daniels A, Aguillón D, Allegri R, Chhatwal J, Day G, Fox NC, Huey E, Ikeuchi T, Jucker M, Lee JH, Levey AI, Levin J, Lopera F, Roh J, Rosa-Neto P, Schofield PR; Dominantly Inherited Alzheimer's Disease–Trials Unit. Bateman RJ, et al. Lancet Neurol. 2025 Apr;24(4):316-330. doi: 10.1016/S1474-4422(25)00024-9. Lancet Neurol. 2025. PMID: 40120616 Clinical Trial.
BACKGROUND: Amyloid plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The Dominant …
BACKGROUND: Amyloid plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's d …
Modelling the Pan-European Economic Burden of Alzheimer's Disease.
Martins R, Urbich M, Brännvall K, Gianinazzi M, Ching JE, Khoury CP, El-Hayek YH. Martins R, et al. JAR Life. 2022 Nov 15;11:38-46. doi: 10.14283/jarlife.2022.7. eCollection 2022. JAR Life. 2022. PMID: 36923231 Free PMC article.
BACKGROUND: Recent advances open the opportunity of altering the course of Alzheimer's disease (AD) through lifestyle-based modifications and novel therapies. Ensuring that society is investing limited budgets in the interventions that have the greatest poten …
BACKGROUND: Recent advances open the opportunity of altering the course of Alzheimer's disease (AD) through lifestyle-b …
Alzheimer's Disease: The Current and Emerging Treatment Approaches.
Pang R, Jia Q, Ma C, Li T, Bi W, Wang H, Liu R, Chen P, Lee ES, Jiang HB. Pang R, et al. Behav Neurol. 2025 Dec 7;2025:9627699. doi: 10.1155/bn/9627699. eCollection 2025. Behav Neurol. 2025. PMID: 41368444 Free PMC article. Review.
Alzheimer's disease (AD) is a chronic progressive neurodegenerative disease characterized by amyloid beta (Abeta) plaques and neurofibrillary tangles (NFTs) as its main pathological features. ...This review summarizes the current traditional drugs that …
Alzheimer's disease (AD) is a chronic progressive neurodegenerative disease characterized by amyloid beta (Abeta …
gamma-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
Schultz SA, Liu L, Schultz AP, Fitzpatrick CD, Levin R, Bellier JP, Shirzadi Z, Joseph-Mathurin N, Chen CD, Benzinger TLS, Day GS, Farlow MR, Gordon BA, Hassenstab JJ, Jack CR Jr, Jucker M, Karch CM, Lee JH, Levin J, Perrin RJ, Schofield PR, Xiong C, Johnson KA, McDade E, Bateman RJ, Sperling RA, Selkoe DJ, Chhatwal JP; Dominantly Inherited Alzheimer Network. Schultz SA, et al. Lancet Neurol. 2024 Sep;23(9):913-924. doi: 10.1016/S1474-4422(24)00236-9. Epub 2024 Jul 26. Lancet Neurol. 2024. PMID: 39074479 Free PMC article.
BACKGROUND: Genetic variants that cause autosomal dominant Alzheimer's disease are highly penetrant but vary substantially regarding age at symptom onset (AAO), rates of cognitive decline, and biomarker changes. Most pathogenic variants that cau …
BACKGROUND: Genetic variants that cause autosomal dominant Alzheimer's disease are highly penetrant but vary substantia …
Something Is Better Than Nothing: The Value of Active Intervention in Stated Preferences for Treatments to Delay Onset of Alzheimer's Disease Symptoms.
Johnson FR, DiSantostefano RL, Yang JC, Reed SD, Streffer J, Levitan B. Johnson FR, et al. Value Health. 2019 Sep;22(9):1063-1069. doi: 10.1016/j.jval.2019.03.022. Epub 2019 Jul 20. Value Health. 2019. PMID: 31511183 Free article.
BACKGROUND: The objective of the study was to understand respondents' willingness to accept hypothetical treatment-related risks in return for the benefit of additional time with normal memory from potential Alzheimer's disease interception therapies. METHODS …
BACKGROUND: The objective of the study was to understand respondents' willingness to accept hypothetical treatment-related risks in return f …
Biomarkers in Alzheimer's disease drug development.
Cummings JL. Cummings JL. Alzheimers Dement. 2011 May;7(3):e13-44. doi: 10.1016/j.jalz.2010.06.004. Epub 2011 May 6. Alzheimers Dement. 2011. PMID: 21550318 Review.
Developing new therapies for Alzheimer's disease (AD) is critically important to avoid the impending public health disaster imposed by this common disorder. Means must be found to prevent, delay the onset, or slow the progression of AD. These go …
Developing new therapies for Alzheimer's disease (AD) is critically important to avoid the impending public health disa …
Amla Therapy as a Potential Modulator of Alzheimer's Disease Risk Factors and Physiological Change.
Teimouri E, Rainey-Smith SR, Bharadwaj P, Verdile G, Martins RN. Teimouri E, et al. J Alzheimers Dis. 2020;74(3):713-733. doi: 10.3233/JAD-191033. J Alzheimers Dis. 2020. PMID: 32083581 Review.
There is currently no effective treatment for Alzheimer's disease (AD), the most common form of dementia. It has been proposed, however, that a modest delay in onset can significantly reduce the number of cases. ...Collectively, this evidence su …
There is currently no effective treatment for Alzheimer's disease (AD), the most common form of dementia. It has been p …
Therapeutic approaches to delay the onset of Alzheimer's disease.
Kumar R, Atamna H. Kumar R, et al. J Aging Res. 2011 Mar 3;2011:820903. doi: 10.4061/2011/820903. J Aging Res. 2011. PMID: 21423548 Free PMC article.
The key cytopathologies in the brains of Alzheimer's disease (AD) patients include mitochondrial dysfunction and energy hypometabolism, which are likely caused by the accumulation of small aggregates of amyloid-beta (Abeta) peptides. Thus, targeting these two …
The key cytopathologies in the brains of Alzheimer's disease (AD) patients include mitochondrial dysfunction and energy …
Automated detection, selection and classification of hippocampal landmark points for the diagnosis of Alzheimer's disease.
Poloni KM, Ferrari RJ. Poloni KM, et al. Comput Methods Programs Biomed. 2022 Feb;214:106581. doi: 10.1016/j.cmpb.2021.106581. Epub 2021 Dec 7. Comput Methods Programs Biomed. 2022. PMID: 34923325
BACKGROUND AND OBJECTIVE: Alzheimer's disease (AD) is a neurodegenerative, progressive, and irreversible disease that accounts for up to 80% of all dementia cases. ...Structural magnetic resonance (MR) imaging has been widely used in studies related to …
BACKGROUND AND OBJECTIVE: Alzheimer's disease (AD) is a neurodegenerative, progressive, and irreversible disease …
115 results